Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

Author(s):
Vasen, H.; Ibrahim, I.; Ponce, C.G.; Slater, E.P.; Matthai, E.; Carrato, A.; Earl, J.; Robbers, K.; Mil, A.M. van; Potjer, T.; Bonsing, B.A.; Cappel, W.H.D.T.N.; Bergman, W.; Wasser, M.; Morreau, H.; Kloppel, G.; Schicker, C.; Steinkamp, M.; Figiel, J.; Esposito, I.; Mocci, E.; Vazquez-Sequeiros, E.; Sanjuanbenito, A.; Munoz-Beltran, M.; Montans, J.; Langer, P.; Fendrich, V.; Bartsch, D.K.
Published
2016
Publication type
Article / Letter to editor

Abstract

Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident. (C) 2016 by American Society of Clinical Oncology

Date issued
2016-06-10
Language
English
Publisher
AMER SOC CLINICAL ONCOLOGY
Is part of
Journal of Clinical Oncology (2016), Vol. 34, no. 17, p. 2010-+
hdl
1887/117204
doi
10.1200/JCO.2015.64.0730